SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

China Biopharmaceutical Says Agreement Covers Six Preclinical Programs

The company said the agreement covers six preclinical asset programs involving antibody-drug conjugates and T-cell engagers.

Related stories